Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp

Daniel Chernavvsky, MD, CRC

Status: Completed

Conditions: Type 1 Diabetes Mellitus

Treatments: Other: Sensor Augmented Pump Therapy; Device: Closed-Loop Control

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT02604524

DP3DK106826-01 (U.S. NIH Grant/Contract)

18529

Details and patient eligibility

About

The biggest challenges for glycemic control during the day time involve meals and exercise variations, which are impacted by age, fitness level, duration, intensity and history of exercise. Meal variability has the benefit that meals are typically announced and quantified. Glucose control around exercise, on the other hand, is more complicated if the patient doesn't announce a change in activity level.

Full description

The object of this study is to evaluate the Closed-Loop Control (CLC) in an environment where muscle glycogen is systematically depleted, glucose uptake systematically increased, and meal sizes are naturally larger than normal: a week of camp at high altitude, with the concomitant variable of oxygen consumption that this environment involves; during the winter, that will expose and challenge the different components of the system during cold temperatures, and with twice daily practice of physical activity designed to deplete glycogen reserves such as skiing.

This proposal aims to demonstrate the superiority of the CLC, also known as Artificial Pancreas (AP), compared to the state-of-the art system available on the market: Sensor-augmented pump (SAP). This system has shown to diminish hypoglycemic events by setting the alarms on the continues glucose monitor (CGM) and taken action, such as performing self-monitoring blood glucose (SMBG) and treating if it is confirm to be low.

Enrollment: 32 patients

Sex: All

Ages: 10 to 25 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: To be eligible for the study, a subject must meet the following:

1. Criteria for documented hyperglycemia (at least 1 must be met):

   • Clinical diagnosis of type 1 diabetes (C-peptide levels and antibody determinations are not required)
   • The diagnosis of type 1 diabetes is based on the investigator's judgment

2. Criteria for requiring insulin at diagnosis (both criteria must be met):

   • Daily insulin therapy for ≥ 12 months
   • Insulin pump therapy for ≥ 3 months

3. Age 10 - 25 years

4. Avoidance of acetaminophen-containing medications (i.e. Tylenol) while wearing the continuous glucose monitor.

5. Willingness to wear a continuous glucose sensor and physiological monitor for the duration of the study

6. Female subjects who are sexually active must be on acceptable method of contraception (e.g. oral contraceptive pill, diaphragm, IUD)

Exclusion Criteria: The presence of any of the following is an exclusion for the study:

1. Diabetic ketoacidosis in the past 6 months

2. Hypoglycemic seizure or loss of consciousness in the past 6 months

3. History of seizure disorder (except for hypoglycemic seizure)

4. History of any heart disease including coronary artery disease, heart failure, or arrhythmias

5. History of altitude sickness

6. Chronic pulmonary conditions that could impair oxygenation

7. Cystic fibrosis

8. Current use of oral glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.

9. History of ongoing renal disease (other than microalbuminuria).

10. Subjects requiring intermediate or long-acting insulin (such as NPH, Detemir or Glargine).

11. Subjects requiring other anti-diabetic medications other than insulin (oral or injectable).

12. Pregnancy

13. Sexually active females who do not practice acceptable contraceptive methods to prevent pregnancy.

14. Presence of a febrile illness within 24 hours of start ski camp or acetaminophen use while wearing the CGM. The camp study subject will not participate in the trial if these conditions are met.

15. Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as:

    • Inpatient psychiatric treatment in the past 6 months
    • Uncontrolled adrenal insufficiency
    • Alcohol abuse

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

32 participants in 2 patient groups, including a placebo group

Closed-Loop Control (CLC) System

Experimental group

Description:

Subjects will use the Closed-Loop Control system in an attempt to maintain blood glucose in a certain range during the day and at night during the trial.

Treatment:

Device: Closed-Loop Control

Sensor Augmented Pump Therapy Group

Placebo Comparator group

Description:

Subjects will manage their own glucose levels during the trial.

Treatment:

Other: Sensor Augmented Pump Therapy